UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of: January, 2007
Commission File Number: 000-50393
NEUROCHEM INC.
275 Armand-Frappier Boulevard
Laval, Quebec
H7V 4A7
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40 F. Form 20-F [ ] Form 40-F [X]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):
Yes [ ] No [X]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):
Yes [ ] No [X]
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g-3 under the Securities Exchange Act of 1934.
Yes [ ] No [X]
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
SIGNATURES:
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
NEUROCHEM INC.
January 16, 2007
By: /s/ David Skinner
---------------------------------------
David Skinner, Vice President,
General Counsel and Corporate Secretary
NEUROCHEM INC.
275 Armand-Frappier Blvd.
[NEUROCHEM (LOGO)] Laval, Quebec, Canada H7V 4A7
________________________________________________________________________________
FOR FURTHER INFORMATION, PLEASE CONTACT:
Lise Hebert, PhD Tel: (450) 680-4572
Vice President, Corporate Communications Fax: (450) 680-4501
lhebert@neurochem.com
- ---------------------
NEUROCHEM ANNOUNCES APPOINTMENT OF JOHN BERNBACH
TO BOARD OF DIRECTORS
LAVAL, QUEBEC, JANUARY 16, 2007 -- Neurochem Inc. (NASDAQ: NRMX, TSX: NRM)
announced today the appointment of Mr. John Bernbach to the Company's Board of
Directors.
John Bernbach is the president and founder of NTM (Not Traditional Media) Inc.,
a company that provides advisory services to marketers looking for integrated
alternative media solutions to more effectively reach and impact target
audiences.
"John is a world leader in advertising and marketing and we are very pleased
that he has agreed to join Neurochem's Board of Directors," said Dr. Francesco
Bellini, Chairman, President and CEO of Neurochem. "His vast experience and
expertise in branding, marketing and advertising strategies will serve Neurochem
well as the Company prepares for the potential commercialization of its product
candidates."
Prior to founding NTM Inc., John Bernbach was chairman and CEO of The Bernbach
Group, an executive management consulting business. From 1995 to 2000, he served
as director, and then chairman and CEO of North American Television based in the
United States, which was successfully sold to the USA Network in 2001. Of his 28
years in the advertising business, 22 were spent with Doyle Dane Bernbach, which
he led into a merger with Needham Harper Worldwide and BBDO, creating the
Omnicom Group, one of the largest, most profitable communications groups in the
world. He served as President and COO of DDB Needham Worldwide for eight years.
ABOUT NEUROCHEM
Neurochem Inc. is focused on the development and commercialization of innovative
therapeutics to address critical unmet medical needs. Eprodisate (KIACTA(TM) -
formerly FIBRILLEX(TM)) is currently being developed for the treatment of
Amyloid A (AA) amyloidosis, and is under regulatory review for marketing
approval by the U.S. Food and Drug Administration and European Medicines Agency.
Tramiprosate (ALZHEMED(TM)), for the treatment of Alzheimer's disease, is
currently in Phase III clinical trials in both North America and Europe and
tramiprosate (CEREBRIL(TM)), for the prevention of
-2-
Hemorrhagic Stroke caused by Cerebral Amyloid Angiopathy, has completed a
Phase IIa clinical trial.
TO CONTACT NEUROCHEM
For additional information on Neurochem and its drug development programs,
please call the North American toll-free number 1-877-680-4500 or visit our Web
Site at www.neurochem.com.
CERTAIN STATEMENTS CONTAINED IN THIS NEWS RELEASE, OTHER THAN STATEMENTS OF FACT
THAT ARE INDEPENDENTLY VERIFIABLE AT THE DATE HEREOF, MAY CONSTITUTE
FORWARD-LOOKING STATEMENTS. SUCH STATEMENTS, BASED AS THEY ARE ON THE CURRENT
EXPECTATIONS OF MANAGEMENT, INHERENTLY INVOLVE NUMEROUS RISKS AND UNCERTAINTIES,
KNOWN AND UNKNOWN, MANY OF WHICH ARE BEYOND NEUROCHEM'S CONTROL. SUCH RISKS
INCLUDE BUT ARE NOT LIMITED TO: THE IMPACT OF GENERAL ECONOMIC CONDITIONS,
GENERAL CONDITIONS IN THE PHARMACEUTICAL INDUSTRY, CHANGES IN THE REGULATORY
ENVIRONMENT IN THE JURISDICTIONS IN WHICH NEUROCHEM DOES BUSINESS, STOCK MARKET
VOLATILITY, FLUCTUATIONS IN COSTS, AND CHANGES TO THE COMPETITIVE ENVIRONMENT
DUE TO CONSOLIDATION, AS WELL AS OTHER RISKS DISCLOSED IN PUBLIC FILINGS OF
NEUROCHEM. CONSEQUENTLY, ACTUAL FUTURE RESULTS MAY DIFFER MATERIALLY FROM THE
ANTICIPATED RESULTS EXPRESSED IN THE FORWARD-LOOKING STATEMENTS. THE READER
SHOULD NOT PLACE UNDUE RELIANCE, IF ANY, ON THE FORWARD-LOOKING STATEMENTS
INCLUDED IN THIS NEWS RELEASE. THESE STATEMENTS SPEAK ONLY AS OF THE DATE MADE
AND NEUROCHEM IS UNDER NO OBLIGATION AND DISAVOWS ANY INTENTION TO UPDATE OR
REVISE SUCH STATEMENTS AS A RESULT OF ANY EVENT, CIRCUMSTANCES OR OTHERWISE.
PLEASE SEE THE ANNUAL INFORMATION FORM FOR FURTHER RISK FACTORS THAT MIGHT
AFFECT THE COMPANY AND ITS BUSINESS.